Celldex Therapeutics (NASDAQ:CLDX) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report released on Wednesday morning,Benzinga reports. Cantor Fitzgerald currently has a $67.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on CLDX. Citigroup began coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Trading Up 3.6 %

Shares of CLDX stock opened at $25.51 on Wednesday. Celldex Therapeutics has a 52-week low of $22.17 and a 52-week high of $53.18. The stock has a fifty day simple moving average of $25.65 and a two-hundred day simple moving average of $31.21.

Insider Activity

In other Celldex Therapeutics news, CEO Anthony S. Marucci acquired 11,500 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its position in Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock valued at $314,190,000 after purchasing an additional 1,167,659 shares during the period. Jennison Associates LLC boosted its stake in shares of Celldex Therapeutics by 32.0% during the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after purchasing an additional 321,325 shares in the last quarter. Emerald Advisers LLC increased its holdings in Celldex Therapeutics by 129.9% during the third quarter. Emerald Advisers LLC now owns 456,202 shares of the biopharmaceutical company’s stock valued at $15,506,000 after buying an additional 257,773 shares during the period. Fisher Asset Management LLC increased its holdings in Celldex Therapeutics by 210.6% during the third quarter. Fisher Asset Management LLC now owns 374,352 shares of the biopharmaceutical company’s stock valued at $12,724,000 after buying an additional 253,808 shares during the period. Finally, Readystate Asset Management LP bought a new position in Celldex Therapeutics in the third quarter worth approximately $6,102,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.